CoChat

Promising candidates from drug clinical trials: Implications for clinical treatment of Alzheimer's disease in China

Open access
Cao, Yuxia, Yu, Feng, Lyu, Yi, Lu, Xianfu · 2022 · Frontiers in Neurology

The DOI matches its Crossref record; 68 of the 69 references it cites were found in a registry or an index.

Abstract

Alzheimer's disease is the most common neurodegenerative disease. Prior to 2017, National Medical Products Administration approved only four drugs to treat Alzheimer's disease, including three cholinesterase inhibitors and one N-methyl-D-aspartate receptor antagonist. We queried ClinicalTrials.gov to better understand Alzheimer's drug development over the past 5 years and found 16 promising candidates that have entered late-stage trials and analyzed their impact on clinical treatment of Alzheimer's disease in China. The 16 compounds selected include disease-modifying therapies and symptomatic therapies. The research and development pipeline now focuses on disease-modifying therapies such as gantenerumab, aducanumab, ALZ-801, ALZT-OP1, donanemab, lecanemab, simufilam, NE3107, semaglutide, and GV-971, which could put an end to the situation where Alzheimer's patients in China have no effective treatment alternatives. The reuse of drugs or combinations currently under investigation for the psychiatric treatment of Alzheimer's disease, including AXS-05, AVP-786, nabilone, brexpiprazole, methylphenidate, and pimavanserin, could provide physicians with additional treatment options. Although most of these drugs have not been explored in China yet, due to the current development trend in this field in China, it is expected that China will be involved in research on these drugs in the future.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fneur.2022.1034243

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Various therapeutic targets in AD and candidates entering late-stage investigations.
Figure 1 Various therapeutic targets in AD and candidates entering late-stage investigations.CC BY · PubMed Central
Figure 2 Chemical structure of ALZ-801 (A), ALZT-OP1 (B), simufilam (C), NE3107 (D), and GV-971 (E).
Figure 2 Chemical structure of ALZ-801 (A), ALZT-OP1 (B), simufilam (C), NE3107 (D), and GV-971 (E).CC BY · PubMed Central
Figure 3 Chemical structure of semaglutide.
Figure 3 Chemical structure of semaglutide.CC BY · PubMed Central
Figure 4 Chemical structure of AXS-05 (A), AVP-786 (B), nabilone (C), brexpiprazole (D), methylphenidate (E), and pimavanserin (F).
Figure 4 Chemical structure of AXS-05 (A), AVP-786 (B), nabilone (C), brexpiprazole (D), methylphenidate (E), and pimavanserin (F).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 16

  1. World Alzheimer's Day. Caring for the Elderly, Please Pay Attention to Alzheimer's Disease. Chinese Center for Disease Control and Prevention (2019).
  2. Jinzhou T Hengge X Luning W. Chinese guidelines for the diagnosis and treatment of Alzheimer's Disease (Version 2020). Chin J Gerontol. (2021) 40: 269– 83. 10.3760/cma.j.issn.0254-9026.2021.03.00135381646 · doi:10.3760/cma.j.issn.0254-9026.2021.03.00135381646
  3. America PRaMo. Researching Alzheimer's Medicines: Setbacks and Stepping Stones, 2012. PhRMA (2016).
  4. Biogen. Aduhelm™ Instruction. FDA (2021).
  5. Cavazzoni P. Fda's Decision to Approve New Treatment for Alzheimer's Disease. FDA (2021).35815585
  6. Dutton G. New Drug Approval Could Be on Horizon for Alzheimer's after 17-Year Drought. BioSpace (2021).
  7. Lecanemab (Also Called Ban2401). ALS News Today (2021).
  8. ALZFORUM. Lecanemab Sweeps up Toxic Aβ Protofibrils, Catches Eyes of Trialists (2021).
  9. MS MW. Simufilam (Pti-125). Alzheimer's News Today (2022).
  10. Shanghai Green Valley Pharmaceuticals Co. L. Sodium Oligomannate Capsules: Chinese Prescribing Information. ALZFORUM (2020).
  11. ALZFORUM. Fits and Starts: Trial Results from the Ctad Conference (2018).
  12. Jacobson M. Advance-1 Phase 2/3 Trial of Axs-05 in Alzheimer's Disease Agitation Topline Results. Axsome (2020).
  13. US. FDA Drug Approval Package: Nuedexta (Dextromethorphan Hydrobromide and Quinidine Sulfate) Capsules. CISION (2011).
  14. Inc AP. Avanir Pharmaceuticals Announces Initiation of Phase Iii Trial of Avp-786 for Agitation in Patients with Alzheimer's Disease (2015).
  15. Avanir. Avanir Pharmaceuticals Announces Initiation of Phase Iii Trial of Avp-786 for Agitation in Patients With Alzheimer's Disease. (2015).
  16. Verghese C Abdijadid S. Methylphenidate. StatPearls (2021). 29494058

Cited by

See all 31

Metadata

Authors
Cao, Y., Yu, F., Lyu, Y., & Lu, X.
Affiliations
  • China Pharmaceutical University (CN)
  • Fudan University (CN)
  • Anhui Medical University (CN)
Corresponding author
  • Lyu, Yi
  • Lu, Xianfu
Venue
Frontiers in Neurology
Published
2022-11-15
Volume
13
Pages
1034243-1034243
ISSN
1664-2295 (ISSN-L)
OpenAlex
W4309212128
Cited by
26
References
69
Citations by year
2026: 7 · 2025: 6 · 2024: 9 · 2023: 4
FWCI
0.65
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Neurology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
Alzheimer's disease, drug development pipeline, late-stage clinical trials, disease-modifying therapy, symptomatic treatment, gantenerumab, aducanumab, donanemab, lecanemab, semaglutide, drug repurposing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.